Drug Discovery
ByIs Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM 2026 with an $840 Million Dark Blue Therapeutics Acquisition?
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at JPM2026 a Bet on the Next Wave of Immuno-Oncology?
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
Can Johnson & Johnson’s $550 Million Vision Care Expansion Drive Local Growth and Innovation?
23 January 2026 Executive Summary Johnson & Johnson’s Vision Care division is advancing a major U.S. expansion project,…
Can Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
